Back to search results

Safety of HRX215 in Patients After Minor and Major Liver Resection

IsraelRecruitingPHASE1, PHASE2

Conditions

Liver Resection · Colorectal Carcinoma Liver Metastases

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic, Rochester, Minnesota, United States

    Contact: Principal Investigator (Patrick Starlinger, M.D Ph.D.)

  • Rabin Medical Center, Petah Tikva, Israel

    Contact: Study coordinator (Eran Sadot, MD, PhD, Professor) · EranSa3@clalit.org.il · +972 54 2222021
    Contact: Principal Investigator (Eran Sadot, M, PhD, Professor)

  • Sheba Medical Center, Ramat Gan, Israel

    Contact: Study coordinator (Niv Pencovich, MD, PhD, Professor) · Niv.Pencovich@sheba.health.gov.il · +972 52 7360036
    Contact: Principal Investigator (Niv Pencovich, MD, PhD, Professor)

  • Tel-Aviv Sourasky MC, Tel Aviv, Israel

    Contact: Study coordinator (Nir Lubezky, MD, PhD, Professor) · nirl@tlvmc.gov.il · +972 52 7360056
    Contact: Principal Investigator (Nir Lubezky, MD, PhD, Professor)
Study leads

  • Linda E Greenbaum, MD

    Study Director

    HepaRegeniX GmbH

  • Patrick Starlinger, MD, PhD

    Principal Investigator

    Mayo Clinic

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)